Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 80

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 2
Chunk 80
---
 rate changes on cash 
     (9) 
     4 
  
    Net increase in cash and restricted cash 
    $353  
    $1,417 

 21 

NET CASH USED IN OPERATING ACTIVITIES. Net cash
used in operating activities was approximately $3,374,000 for the six months ended September 30, 2025, compared to approximately $3,962,000
for the same period in 2024. The decrease was primarily driven by a lower net loss in the current period. However, this improvement was
largely offset by changes in working capital, including decreases of approximately $796,000 in amounts due to related parties, $420,000
in accounts payable and other current liabilities, and $211,000 in prepaid expenses and other current assets, as well as $111,000 of lower
non-cash charges compared with the prior year, for a total offset of approximately $1,538,000.

NET CASH PROVIDED BY FINANCING ACTIVITIES.
Net cash provided by financing activities decreased by approximately $1,640,000 for the six months ended September 30, 2025. During the
current period, we raised $3,744,000, net of placement agent fees and offering costs, partially offset by approximately $9,000 used for
tax withholding on restricted stock unit settlements. In comparison, for the six months ended September 30, 2024, we raised approximately
$5,384,000, net of placement agent fees and offering costs, from the sale and issuance of common stock and warrants in connection with
a public offering, as well as the exercise of 3,750 Class A warrants and 36,000 Class B warrants. This amount was partially offset by
approximately $9,000 for tax withholding on restricted stock unit settlements, resulting in net cash provided by financing activities
of approximately $5,375,000. 

Material Cash Requirements 

We expect our clinical trial expenses for the
planned oncology trial in Australia to increase for the foreseeable future. Those increases in clinical trial expenses include the cost
of manufacturing additional Hemopurifiers.

In addition, we have entered into leases for our
headquarters, laboratory and manufacturing facilities. We expect our rent payments to continue to increase for the foreseeable future.

Future capital requirements will depend upon many
factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs